Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma

被引:50
作者
Liu, Ying Y. [1 ]
Morreau, Hans [2 ]
Kilevit, Job [3 ,4 ]
Romijn, Johannes A. [1 ]
Carrasco, Nancy [5 ]
Smit, Johannes W. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol C4 R, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[5] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
关键词
D O I
10.1530/EJE-07-0492
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The microscopic distinction between benign and malignant thyroid lesions in clinical practice is still largely based on conventional histology. This study was performed to evaluate the diagnostic value of galectin-3 (Gal-3), Hector Battifora mesothelial-1 (HBME-1), cytokeratin (CK)-19, CBP P300-interacting transactivator with glutamic acid E- and aspartic acid D-rich C-terminal domain (CITED-1), fibronectin (FN)-1, peroxisome proliferator-activated receptor (PPAR)-gamma, and intracellular sodium/iodide symporter (iNIS) immunostaining in a large panel of thyroid neoplasms. Our study differed from earlier ones with regard to the identification of optimal semiquantitative cut-off levels using receiver operator curve (ROC) analysis and hierarchical cluster analysis. Methods: We used tissue arrays containing 177 thyroid tissues: 100 benign tissues (including normal thyroid, Graves disease, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)). Antibody staining was scored semiquantitatively based on the ROC analyses and with hierarchical cluster analysis. Results: In general, we found overexpression of FN-1, CITED-1, Gal-3, CK-19, HBME-1, and iNIS in malignant thyroid lesions. Gal-3, FN-1, and iNIS had the highest accuracy in the differential diagnosis of follicular lesions. A panel of Gal-3, FN-1, and iNIS, identified by hierarchical cluster analysis, had a 98% accuracy to differentiate between FA and malignant thyroid lesions. In addition, HBME-1 was found to be useful in the differentiation between FA and FVPTC (accuracy 88%). Conclusion: We conclude that identifying optimal antibody panels with cluster analysis increases the diagnostic value in the differential diagnosis of thyroid neoplasms, the combination of FN-1, Gal-3, and iNIS having the best accuracy(98%).
引用
收藏
页码:375 / 384
页数:10
相关论文
共 48 条
[1]   Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions [J].
Bartolazzi, A ;
Gasbarri, A ;
Papotti, M ;
Bussolati, G ;
Lucante, T ;
Khan, A ;
Inohara, H ;
Marandino, F ;
Orlandi, F ;
Nardi, F ;
Vecchione, A ;
Tecce, R ;
Larsson, O .
LANCET, 2001, 357 (9269) :1644-1650
[2]   Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules [J].
Beesley, MF ;
McLaren, KM .
HISTOPATHOLOGY, 2002, 41 (03) :236-243
[3]   Na+/I- symporter distribution in human thyroid tissues:: An immunohistochemical study [J].
Caillou, B ;
Troalen, F ;
Baudin, E ;
Talbot, M ;
Filetti, S ;
Schlumberger, M ;
Bidart, JM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :4102-4106
[4]   Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1 [J].
Casey, MB ;
Lohse, CM ;
Lloyd, RV .
ENDOCRINE PATHOLOGY, 2003, 14 (01) :55-60
[5]   PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma [J].
Castro, P ;
Rebocho, AP ;
Soares, RJ ;
Magalhaes, J ;
Roque, L ;
Trovisco, V ;
de Castro, IV ;
Cardoso-de-Oliveira, M ;
Fonseca, E ;
Soares, P ;
Sobrinho-Simoes, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :213-220
[6]   Detection of the PAX8-PPARγ fusion oncogene in both follicular thyroid carcinomas and adenomas [J].
Cheung, L ;
Messina, M ;
Gill, A ;
Clarkson, A ;
Learoyd, D ;
Delbridge, L ;
Wentworth, J ;
Philips, J ;
Clifton-Bligh, R ;
Robinson, BG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01) :354-357
[7]   Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy [J].
de Matos, PS ;
Ferreira, AP ;
Facuri, FD ;
Assumpçao, LVM ;
Metze, K ;
Ward, LS .
HISTOPATHOLOGY, 2005, 47 (04) :391-401
[8]   Predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer cases [J].
Dohán, O ;
Baloch, Z ;
Bánrévi, Z ;
Livolsi, V ;
Carrasco, N .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06) :2697-2700
[9]   Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups [J].
Eszlinger, M ;
Wiench, M ;
Jarzab, B ;
Krohn, K ;
Beck, M ;
Läuter, J ;
Gubala, E ;
Fujarewicz, K ;
Swierniak, A ;
Paschke, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (05) :1934-1942
[10]   Advancing the molecular diagnosis of thyroid nodules: Defining benign lesions by molecular profiling [J].
Finley, DJ ;
Lubitz, CC ;
Wei, C ;
Zhu, BX ;
Fahey, TJ .
THYROID, 2005, 15 (06) :562-568